Company intelligence / Profile preview

NatiVita

Beshankovichy, Vitebsk region, Belarusnativita.ind.br ↗

Ownership: Private
Development stage: Other

Overview

NatiVita has developed a proprietary lung-cancer vaccine using Cuban technology that demonstrated improved five-year survival rates among patients with non-small-cell lung carcinoma compared to standard care—16.6% vs. 6.2%—according to clinical trial data reported as of February 2019. The company has also registered numerous oncology and specialty products within Belarus and seeks further international expansion into Middle Eastern markets such as Syria and Iraq.

Therapeutic areas: Infectious DiseasesNeurologyOncology
Modalities: Monoclonal antibodyVaccineBiologicSmall molecule
Industry: Biotech

Drug pipeline

1 asset

Aviga

Partnerships

AB ZiaValdaUniPharma SlovakiaNatco Pharma IndiaCuban partners

Beyond the preview

Go deeper on NatiVita.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NatiVita.

Explore the full profile